VOLUNTARY ANNOUNCEMENT - LANOVA MEDICINES PRESENTED PRELIMINARY CLINICAL DATA ON MK-2010/LM-299 AT AACR 2026

NEXT DAY DISCLOSURE RETURN

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN PHASE III CLINICAL TRIAL OF TECOTABART VEDOTIN “CLDN18.2 ADC” FOR FIRST-LINE TREATMENT OF GASTRIC AND GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF THE FIRST PATIENT IN THE PHASE II CLINICAL TRIAL OF KYLO-11 “LPA SIRNA” IN THE UNITED STATES

VOLUNTARY ANNOUNCEMENT - NALDEMEDINE APPROVED FOR MARKETING IN THE GREATER BAY AREA

VOLUNTARY ANNOUNCEMENT - APPLICATION FOR CLINICAL TRIAL ON TQB3205 “PAN-KRAS INHIBITOR” APPROVED BY THE FDA

MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 2026

COMPLETION OF SHARE TRANSACTION - ACQUISITION OF 100% EQUITY INTEREST IN HYGIEIA INVOLVING THE ISSUE OF CONSIDERATION SHARES UNDER GENERAL MANDATE